Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are expected to live for at least 12 weeks.
• People whose non-small cell lung cancer (NSCLC) tumour cells show high levels of a protein called c-Met, as confirmed by a specific laboratory test arranged by the trial sponsor.
• People whose NSCLC has been confirmed through a tissue or cell sample and has either spread to nearby areas or to other parts of the body.
• People whose cancer has been tested and has a known result for a gene change called EGFR.
• People whose cancer has gene changes in genes other than EGFR (confirm with trial site).
• People whose cancer can be measured using standard imaging criteria (called RECIST version 1.1).
• People who are relatively well and able to carry out everyday activities, as rated 0 or 1 on a standard medical fitness scale.
• People who have received no more than one prior course of chemotherapy for advanced or spread NSCLC.
• People whose cancer has gotten worse after at least one prior treatment for advanced or spread NSCLC.

Who may not be able to join:

• People whose NSCLC is of a specific tumour type called adenosquamous, neuroendocrine, or sarcomatoid.
• People whose cancer has certain EGFR gene mutations (such as Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
• People who have previously received c-Met-targeted antibody treatments, a drug called telisotuzumab vedotin, or certain antibody-drug treatments related to c-Met or a specific chemical compound called monomethylauristatin E.
• People who have previously been treated with a chemotherapy drug called docetaxel.
• People whose cancer has spread to the brain or spinal cord, unless they have already received adequate treatment for those areas and meet specific conditions set out in the trial protocol (confirm with trial site).
• People with a history of another cancer, except in certain cases described in the trial protocol (confirm with trial site).
• People with a history of certain serious lung conditions, including pulmonary fibrosis, organising pneumonia, or drug-related lung inflammation, or who show signs of active lung inflammation on a recent CT scan.
• People who still have unresolved side effects rated moderate or worse (Grade 2 or above) from previous cancer treatment, except for hair loss or anaemia. People with hormone problems caused by prior treatment who are stable on hormone replacement may still be considered (confirm with trial site).
• People who have had major surgery within 21 days before joining the trial.
• People with certain serious ongoing health conditions as listed in the trial protocol (confirm with trial site).
• People with significant liver disease, including hepatitis, active heavy alcohol use, or cirrhosis.
• People with moderate or severe swelling due to fluid build-up in the body or lymph system (Grade 2 or above).
• People with moderate or severe fluid build-up in the abdomen or around the lungs (Grade 2 or above).
• People with moderate or severe nerve damage causing symptoms such as numbness or pain (Grade 2 or above).
• People with an active bacterial or viral infection that is not under control.
• People with an active condition affecting the surface of the eye.

Important: Always verify eligibility with the trial site directly before applying.